$22.12
0.210.96%
At close: -
$22.11
-0.01-0.05%
After Hours: 5:50 PM EDT
Comments
Loading...
Pfizer Analyst Ratings and Price Targets | NYSE:PFE | Benzinga
Pfizer Inc has a consensus price target of $33.71 based on the ratings of 23 analysts. The high is $50 issued by HSBC on July 14, 2023. The low is $24 issued by UBS on April 8, 2025. The 3 most-recent analyst ratings were released by UBS, Goldman Sachs, and Guggenheim on April 8, 2025, April 8, 2025, and February 10, 2025, respectively. With an average price target of $27.33 between UBS, Goldman Sachs, and Guggenheim, there's an implied 23.62% upside for Pfizer Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Goldman Sachs
UBS
Citigroup
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Pfizer
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 8.55% | UBS | Trung Huynh63% | $28 → $24 | Maintains | Neutral | Get Alert |
| 04/08/2025 | Buy Now | 13.07% | Goldman Sachs | Asad Haider 38% | $32 → $25 | Downgrade | Buy → Neutral | Get Alert |
| 03/18/2025 | Buy Now | — | Guggenheim | Vamil Divan72% | — | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | — | Guggenheim | Vamil Divan72% | — | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | 49.25% | Guggenheim | Vamil Divan72% | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
| 02/05/2025 | Buy Now | 26.64% | UBS | Colin Bristow39% | $29 → $28 | Maintains | Neutral | Get Alert |
| 01/28/2025 | Buy Now | 31.16% | Citigroup | Andrew Baum70% | $30 → $29 | Maintains | Neutral | Get Alert |
| 01/08/2025 | Buy Now | 31.16% | UBS | Colin Bristow39% | $31 → $29 | Maintains | Neutral | Get Alert |
| 12/18/2024 | Buy Now | 44.73% | Truist Securities | Srikripa Devarakonda38% | $36 → $32 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | 49.25% | Guggenheim | Vamil Divan72% | $35 → $33 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | 31.16% | B of A Securities | Tim Anderson53% | → $29 | Reinstates | → Neutral | Get Alert |
| 11/15/2024 | Buy Now | 13.07% | Wolfe Research | Alexandria Hammond37% | → $25 | Initiates | → Underperform | Get Alert |
| 10/30/2024 | Buy Now | 40.21% | Morgan Stanley | Terence Flynn66% | $30 → $31 | Maintains | Equal-Weight | Get Alert |
| 10/25/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 10/23/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 10/17/2024 | Buy Now | 44.73% | Bernstein | Courtney Breen1% | → $32 | Initiates | → Market Perform | Get Alert |
| 10/11/2024 | Buy Now | 35.69% | Morgan Stanley | Terence Flynn66% | $31 → $30 | Maintains | Equal-Weight | Get Alert |
| 10/03/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 08/08/2024 | Buy Now | 53.78% | Daiwa Capital | Narumi Nakagiri23% | $28 → $34 | Upgrade | Neutral → Outperform | Get Alert |
| 07/31/2024 | Buy Now | 40.21% | Morgan Stanley | Terence Flynn66% | $29 → $31 | Maintains | Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | 44.73% | Barclays | Carter Gould56% | $30 → $32 | Maintains | Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | 35.69% | Wells Fargo | Mohit Bansal69% | $28 → $30 | Maintains | Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 07/31/2024 | Buy Now | 40.21% | UBS | Colin Bristow39% | $30 → $31 | Maintains | Neutral | Get Alert |
| 07/12/2024 | Buy Now | 35.69% | UBS | Colin Bristow39% | $28 → $30 | Maintains | Neutral | Get Alert |
| 07/10/2024 | Buy Now | 35.69% | Barclays | Carter Gould56% | $28 → $30 | Maintains | Equal-Weight | Get Alert |
| 07/10/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 07/01/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 05/02/2024 | Buy Now | 31.16% | Morgan Stanley | Terence Flynn66% | $28 → $29 | Maintains | Equal-Weight | Get Alert |
| 05/02/2024 | Buy Now | 62.82% | BMO Capital | Evan David Seigerman44% | $33 → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 04/18/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/15/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/05/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/31/2024 | Buy Now | 31.16% | Morgan Stanley | Terence Flynn66% | $28 → $29 | Maintains | Equal-Weight | Get Alert |
| 03/22/2024 | Buy Now | — | Argus Research | David Toung71% | — | Downgrade | Buy → Hold | Get Alert |
| 03/04/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/01/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 62.82% | Guggenheim | Vamil Divan72% | → $36 | Initiates | → Buy | Get Alert |
| 01/31/2024 | Buy Now | 26.64% | UBS | Colin Bristow39% | $29 → $28 | Maintains | Neutral | Get Alert |
| 01/31/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 01/17/2024 | Buy Now | 31.16% | UBS | Colin Bristow39% | $27 → $29 | Maintains | Neutral | Get Alert |
| 01/09/2024 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 01/04/2024 | Buy Now | 44.73% | TD Cowen | Steve Scala68% | → $32 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/14/2023 | Buy Now | 26.64% | Wells Fargo | Mohit Bansal69% | $35 → $28 | Maintains | Equal-Weight | Get Alert |
| 12/14/2023 | Buy Now | 103.53% | Cantor Fitzgerald | Louise Chen51% | $75 → $45 | Maintains | Overweight | Get Alert |
| 12/14/2023 | Buy Now | 62.82% | Truist Securities | Robyn Karnauskas55% | $42 → $36 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 22.12% | UBS | Colin Bristow39% | $34 → $27 | Maintains | Neutral | Get Alert |
| 12/14/2023 | Buy Now | 26.64% | Barclays | Carter Gould56% | $34 → $28 | Maintains | Equal-Weight | Get Alert |
| 12/04/2023 | Buy Now | 89.96% | Truist Securities | Robyn Karnauskas55% | → $42 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 11/01/2023 | Buy Now | 53.78% | Barclays | Carter Gould56% | $35 → $34 | Maintains | Equal-Weight | Get Alert |
| 11/01/2023 | Buy Now | 67.35% | Morgan Stanley | Terence Flynn66% | $39 → $37 | Maintains | Equal-Weight | Get Alert |
| 10/20/2023 | Buy Now | 53.78% | UBS | Colin Bristow39% | $36 → $34 | Assumes | Neutral → Neutral | Get Alert |
| 10/17/2023 | Buy Now | 89.96% | Truist Securities | Robyn Karnauskas55% | $62 → $42 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | 76.39% | Morgan Stanley | Terence Flynn66% | $40 → $39 | Maintains | Equal-Weight | Get Alert |
| 10/17/2023 | Buy Now | 58.3% | Wells Fargo | Mohit Bansal69% | $39 → $35 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 49.25% | BMO Capital | Evan David Seigerman44% | $44 → $33 | Maintains | Outperform | Get Alert |
| 10/16/2023 | Buy Now | 58.3% | Citigroup | Andrew Baum70% | $42 → $35 | Maintains | Neutral | Get Alert |
| 10/16/2023 | Buy Now | 53.78% | JP Morgan | Chris Schott59% | $36 → $34 | Maintains | Neutral | Get Alert |
| 10/16/2023 | Buy Now | 58.3% | Wells Fargo | Mohit Bansal69% | $39 → $35 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 76.39% | Jefferies | Akash Tewari43% | $38 → $39 | Upgrade | Hold → Buy | Get Alert |
| 10/06/2023 | Buy Now | 62.82% | JP Morgan | Chris Schott59% | $39 → $36 | Maintains | Neutral | Get Alert |
| 10/02/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 09/18/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 180.42% | Truist Securities | Robyn Karnauskas55% | → $62 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/30/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/02/2023 | Buy Now | 180.42% | Truist Securities | Robyn Karnauskas55% | $64 → $62 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 80.91% | Morgan Stanley | Terence Flynn66% | $42 → $40 | Maintains | Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | 99% | BMO Capital | Evan David Seigerman44% | $45 → $44 | Maintains | Outperform | Get Alert |
| 07/21/2023 | Buy Now | 89.96% | Morgan Stanley | Terence Flynn66% | $43 → $42 | Maintains | Equal-Weight | Get Alert |
| 07/14/2023 | Buy Now | 126.14% | HSBC | Rajesh Kumar63% | → $50 | Initiates | → Buy | Get Alert |
| 07/11/2023 | Buy Now | 94.48% | Morgan Stanley | Terence Flynn66% | $43 → $43 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/11/2023 | Buy Now | 71.87% | Barclays | Carter Gould56% | $40 → $38 | Maintains | Equal-Weight | Get Alert |
| 06/29/2023 | Buy Now | 80.91% | Credit Suisse | Trung Huynh63% | $47 → $40 | Downgrade | Outperform → Neutral | Get Alert |
| 06/23/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | $75 → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 06/22/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 05/17/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 05/11/2023 | Buy Now | 71.87% | Daiwa Capital | Narumi Nakagiri23% | $51 → $38 | Downgrade | Outperform → Neutral | Get Alert |
| 05/03/2023 | Buy Now | 112.57% | Credit Suisse | Trung Huynh63% | $50 → $47 | Maintains | Outperform | Get Alert |
| 05/03/2023 | Buy Now | 80.91% | Barclays | Carter Gould56% | $43 → $40 | Maintains | Equal-Weight | Get Alert |
| 04/21/2023 | Buy Now | 103.53% | B of A Securities | Geoff Meacham60% | $50 → $45 | Maintains | Neutral | Get Alert |
| 04/12/2023 | Buy Now | 94.48% | Barclays | Carter Gould56% | $44 → $43 | Maintains | Equal-Weight | Get Alert |
| 04/10/2023 | Buy Now | 99% | Morgan Stanley | Terence Flynn66% | $45 → $44 | Maintains | Equal-Weight | Get Alert |
| 03/17/2023 | Buy Now | 99% | Wells Fargo | Mohit Bansal69% | $50 → $44 | Maintains | Equal-Weight | Get Alert |
| 03/06/2023 | Buy Now | 94.48% | Jefferies | Akash Tewari43% | → $43 | Initiates | → Hold | Get Alert |
| 02/07/2023 | Buy Now | 130.66% | Daiwa Capital | Narumi Nakagiri23% | → $51 | Upgrade | Neutral → Outperform | Get Alert |
| 02/01/2023 | Buy Now | 103.53% | Morgan Stanley | Terence Flynn66% | $53 → $45 | Maintains | Equal-Weight | Get Alert |
| 02/01/2023 | Buy Now | 239.21% | Cantor Fitzgerald | Louise Chen51% | → $75 | Reiterates | → Overweight | Get Alert |
| 02/01/2023 | Buy Now | 126.14% | Credit Suisse | Trung Huynh63% | $54 → $50 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 139.71% | BMO Capital | Evan David Seigerman44% | $55 → $53 | Maintains | Outperform | Get Alert |
| 02/01/2023 | Buy Now | 99% | Barclays | Carter Gould56% | $49 → $44 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Pfizer (PFE) stock?
The latest price target for Pfizer (NYSE:PFE) was reported by UBS on April 8, 2025. The analyst firm set a price target for $24.00 expecting PFE to rise to within 12 months (a possible 8.55% upside). 38 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pfizer (PFE)?
The latest analyst rating for Pfizer (NYSE:PFE) was provided by UBS, and Pfizer maintained their neutral rating.
When was the last upgrade for Pfizer (PFE)?
The last upgrade for Pfizer Inc happened on August 8, 2024 when Daiwa Capital raised their price target to $34. Daiwa Capital previously had a neutral for Pfizer Inc.
When was the last downgrade for Pfizer (PFE)?
The last downgrade for Pfizer Inc happened on April 8, 2025 when Goldman Sachs changed their price target from $32 to $25 for Pfizer Inc.
When is the next analyst rating going to be posted or updated for Pfizer (PFE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Pfizer (PFE) correct?
While ratings are subjective and will change, the latest Pfizer (PFE) rating was a maintained with a price target of $28.00 to $24.00. The current price Pfizer (PFE) is trading at is $22.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.